CC
CUE icon

Corton Capital’s Cue Biopharma CUE Stock Holding History

Corton Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-464
Closed -$68K – 370
2022
Q1 		$68K Buy
+464
New +$98.4K 0.03% 401

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Corton Capital's CUE Position: Q2 2022 in Review

Corton Capital sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 464 shares — an estimated $68K sold.

Corton Capital first reported a position in CUE in Q1 2022 and held it in 1 quarter. The position peaked at $68K in Q1 2022. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • Corton Capital reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • Corton Capital sold 464 Cue Biopharma shares in Q2 2022, an estimated $68K.
  • Corton Capital first reported a position in Cue Biopharma in Q1 2022 and held it in 1 quarter.
  • Corton Capital's Cue Biopharma position peaked at $68K in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Corton Capital's 13F filing for Q2 2022, filed 15 Aug 2022.